ImmunoGen, Inc. (NASDAQ:IMGN) Given Consensus Rating of "Hold" by Analysts

Last updated on Sunday, June 13, 2021 | 2021 MarketBeat

Shares of ImmunoGen, Inc. (NASDAQ:IMGN) have earned an average rating of "Hold" from the nine ratings firms that are currently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and four have assigned a buy rating to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $10.00.

IMGN has been the subject of several recent analyst reports. Zacks Investment Research cut shares of ImmunoGen from a "hold" rating to a "sell" rating and set a $9.50 price objective for the company. in a research report on Thursday, February 18th. TheStreet cut shares of ImmunoGen from a "c" rating to a "d+" rating in a research report on Friday, March 26th. HC Wainwright increased their price objective on shares of ImmunoGen from $11.00 to $12.00 and gave the stock a "buy" rating in a research report on Tuesday, February 16th. Finally, William Blair restated an "outperform" rating on shares of ImmunoGen in a report on Monday, May 10th.

A number of large investors have recently bought and sold shares of IMGN. Fisher Asset Management LLC lifted its stake in shares of ImmunoGen by 3.7% in the first quarter. Fisher Asset Management LLC now owns 41,942 shares of the biotechnology company's stock valued at $340,000 after buying an additional 1,487 shares in the last quarter. Scotia Capital Inc. lifted its stake in shares of ImmunoGen by 7.8% in the fourth quarter. Scotia Capital Inc. now owns 21,860 shares of the biotechnology company's stock valued at $141,000 after buying an additional 1,582 shares in the last quarter. Fernwood Investment Management LLC lifted its stake in shares of ImmunoGen by 1.3% in the first quarter. Fernwood Investment Management LLC now owns 151,340 shares of the biotechnology company's stock valued at $1,226,000 after buying an additional 2,000 shares in the last quarter. MML Investors Services LLC lifted its stake in shares of ImmunoGen by 21.5% in the first quarter. MML Investors Services LLC now owns 14,249 shares of the biotechnology company's stock valued at $115,000 after buying an additional 2,517 shares in the last quarter. Finally, Penserra Capital Management LLC lifted its stake in shares of ImmunoGen by 193.3% in the fourth quarter. Penserra Capital Management LLC now owns 4,370 shares of the biotechnology company's stock valued at $28,000 after buying an additional 2,880 shares in the last quarter. Institutional investors and hedge funds own 91.37% of the company's stock.

Shares of NASDAQ IMGN opened at $6.48 on Friday. ImmunoGen has a 52-week low of $3.38 and a 52-week high of $10.88. The company has a 50 day simple moving average of $7.02. The firm has a market cap of $1.30 billion, a PE ratio of -23.14 and a beta of 1.36.

ImmunoGen (NASDAQ:IMGN) last posted its quarterly earnings data on Monday, May 10th. The biotechnology company reported ($0.17) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.19) by $0.02. ImmunoGen had a negative net margin of 36.62% and a negative return on equity of 169.72%. The company had revenue of $15.70 million during the quarter, compared to analysts' expectations of $17.52 million. ImmunoGen's revenue for the quarter was up 18.0% on a year-over-year basis. On average, equities research analysts expect that ImmunoGen will post -0.75 earnings per share for the current fiscal year.

About ImmunoGen

ImmunoGen, Inc, a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. Its product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha, which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and IMGN632, a CD123-targeting ADC that is in Phase I clinical trial for treating AML and blastic plasmacytoid dendritic cell neoplasm.

Featured Story: The Role of a Fiduciary and Individual Investors

Analyst Recommendations for ImmunoGen (NASDAQ:IMGN)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]

Featured Article: How is a price target determined?


7 Internet of Things Stocks That Are a Perfect Fit to Our Connected Future

When you say the Internet of Things (IoT) you may get different responses. I like to think of it broadly as being about connection. It’s about devices that can connect with each other, and with the internet. And this provides users with the solutions that are making our lives more convenient.

The most basic, and ubiquitous, example of an IoT device is the smartphone that many of us have with us at all times. But think about what that has led to. Home assistants, security cameras, fitness apps, and so much more are all enabled by the internet of things.

IoT took on even more importance in the pandemic as businesses had to find a way to ensure the security and viability of their networks even as their employees were scattered remotely. This created demand for edge and cloud computing solutions that are also facilitated by the internet of things.

And yes, this is just the start. The need for more and more data is powering demand for IoT solution in areas such as autonomous vehicles.

But the good news is that this is an area that is still very much in its growth phase. And that means there is no lack of companies that you can find to trade in this sector. To help you get started, we’ve put together this special presentation that highlights seven such companies and the reasons why we believe they merit adding to your portfolio.

View the "7 Internet of Things Stocks That Are a Perfect Fit to Our Connected Future".


MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.